ABBV - AbbVie succeeds in mid-stage trial for overran cancer drug Elahere
2024-06-06 09:08:10 ET
More on AbbVie
- AbbVie: Turnaround Lurking After The Correction Pain (Upgrade)
- AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now
- Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered
- AbbVie doses first patient in phase 3 trial of multiple myeloma asset
- Emerging and Chinese pharmas playing greater role in oncology drug development